Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great question (again) and PS Targeting is HUGE ....as for patent protection ? We have that under control
From dosage specific patents to new IIS ..I mean new combination patents to delivery method such as subcutaneous ...to NEW medical device to be used for drug delivery ...etc etc and all mixes in between ...patents for IP assets affiliated with PS Targeting is no problem
Varisacumab anti VEGF coming soon
A side note for all the CDMO manufacturing space that will be required ...how has BOD Mark Bamforth secured the contracts for Arranta at 650 Pleasant St Watertown MA and plan on running 2 -12 hour shifts they are proposing ....when he sits on Avid CDMO BOD and can't promise guarantees for full capacity and CDMO making deals with ThermoFisher
Looks like they don't want to spill the brand just yet about expansion of Avid ...or they are breaking the law using confidential data info etc to benefit themselves ...I say they will do the right thing
____
Extending the market exclusivity of therapeutic antibodies through dosage patents
...
...
Dosage patents are one way to extend the market exclusivity of an approved drug beyond the lifetime of the patent that protects the drug as such. Dosage patents may help to compensate the applicant for the long period where the active pharmaceutical ingredient as such is already under patent prosecution, but not on the market yet, due to lengthy development and approval procedures. This situation erodes part of the time the drug is marketed under patent protection. Dosage patents filed at a later date can provide remedy for this problem.
...
...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968089/
_____
Intravenous-to-Subcutaneous (IV-to-SC) Drug Migration Market, 2024
Dublin, March 20, 2019 (GLOBE NEWSWIRE) -- The "Intravenous-to-Subcutaneous Drug Repositioning" report has been added to ResearchAndMarkets.com's offering.
As the pace of competition increases within the pharmaceutical and biotech industries, the concept of life cycle management is becoming a key component of drug product management. Much of the recent emphasis in this area has centered on efforts to extend patent rights protection.
While reformulation has been and is an important approach, efforts to prolong IP benefits have only recently involved IV-to-SC drug re-engineering.
...
...
https://www.globenewswire.com/news-release/2019/03/20/1757985/0/en/Intravenous-to-Subcutaneous-IV-to-SC-Drug-Migration-Market-2024.html
_____
Laura Benjamin - CEO Oncologie Inc re: PS Targeting biomarkers Avid Bioservices CDMO
https://podcasts.apple.com/us/podcast/laura-benjamin-oncologie-part-of-the-nametag-series/id1088325796?i=1000450524353
______________
650 Pleasant St
PB-2019-05 SP
650 Pleasant Street
Demo 5,000 s.f. of existing building to construct new 15,700 s.f. addition for office, lab/manufacturing
PB Hearing
11/13/2019 New
https://www.watertown-ma.gov/748/Zoning-Relief-PetitionsCases
_____________
Arranta - 12 hour shifts
https://www.watertown-ma.gov/DocumentCenter/View/28260/06_Arranta-commitment-to-the-TDM-Regulations_Oct-8-2019
Oncologie at SITC 2019 Nov 6-10
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=152095761
Omeros already making Dr Benjamin move quicker, as Omeros plain out states the vital importance of PS Targeting on Sept 10, 2019 ( Omeros has more data coming ..)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=152095761
Laura Benjamin recent interview 27 minutes as she discusses IP assets part of 15% net sales heading to Avid Bioservices CDMO ( Varisacumab and Bavituximab )
She says in the interview an assay completed for diagnostic re: Varisacumab and very interesting ....also clear out admits she was impressed with how it was Bavituximab that led to MOS when patients moved on to another treatment ( which is what Merck seen with Keytruda) and ex Eli Lilly = Alex Azar ...now US Secretary of State Department Health Human Services knows well due to complaints filed to FDA to release the info and have Bavi approved
Everyone needs it ...all Big Pharma and even Lockheed Martin that filed for a PS Targeting patent to use Perforene (graphene) filter to extract SUBSTANCES out of blood
The ONLY bad substances on stressed cells contain flipped PS and Dr Laura Benjamin states that all stressed cells HAVE flipped PS and there is SO much more being gathered collected and submitted ...maybe our Chair Joseph Carleone had ties with Byron ties over at Keystone etc : )
Altravue Capital knows Richard Aldrich and family ...new NEW ISS prepared now although some request I stop giving out free for all but since I say trust no one...all will have it
____
Graphene-based filter for isolating a substance from blood
Filed = June 21, 2013
Awarded = Feb 21, 2017 (Stafford shows up)
A device isolates a substance from blood. The substance includes particles with an effective diameter that is within a range defined by effective diameters of constituents of blood. The device comprises a first sheet of graphene including a first plurality of apertures. The first plurality of apertures are configured to pass objects with an effective diameter less than or equal to the effective diameter of the particles of the substance. The device comprises a second sheet of graphene including a second plurality of apertures. The second plurality of apertures are configured to pass objects with an effective diameter less than the effective diameter of the particles of the substance. The device may be configured to include a conduit system. The device may be configured to operate according to a reversible cycle.
http://patft.uspto.gov/netacgi/nph-Parser?d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9572918.PN.&OS=PN/9572
918&RS=PN/9572918
Patent Inventor
Byron W. Tietjen
Paul Declan Mountcastle
Svetlana Monakhova Bachmann
https://pubchem.ncbi.nlm.nih.gov/patent/US9572918
————
Altravue Capital LLC adds another 114,570 shares ...now has 2,233,382
ALTRAVUE CAPITAL, LLC 09/30/2019 2,223,382 114,570 5.43 11,361
Avid CDMO BODs never responded for the full and complete details of all IP assets
The one number mentioned was in the range around 15% net sales
Most BPs with an FDA approved drug owe much more than that due to strings attached leading up to such approvals...so 15% CAN be sufficient along with all manufacturing rights
Speaking of manufacturing, Avid CDMO already hinted at a deal with Thermofisher would be considered ..(they said that AFTER Ampersand Capital / Bamforth CEO to Arranta were in final arrangements with ThermoFisher ...)
Imagine that, Avid CDMO BOD can't publicly tell us " we DEFINITELY need to expand" on the Avid side...yet Ampersand Capital keeps pushing out CDMO as their latest one is 650 Pleasant St Watertown MA with Glasgow UK buddy Mr Baird pulling the strings for now
Did you listen to Dr Benjamin interview I posted? Pay attention to how she describes the timeline in organizing Oncologie Inv and who she said she went to FIRST for funding ?? Lol
Pivotal Bioventure was created in 2017
Stafford shows up in 2017
PS Targeting Bavi patients lived long .. and helped Keytruda in 2017
It is funny seeing some try and cover their tracks ...I think I need a Lockheed Martin perforene filter to sift thru all the flipped PS and I imagine there is a very good reason why Omeros wanted the public to know about PS Targeting
More PS Targeting talk ..looks like the IP assets are gaining momentum
Dr Laura Benjamin said many in her circle are well aware of PS Targeting ...did you listen? : )
SITC = Society for Immumotherapy of Cancer
https://sitc.sitcancer.org/2019/abstracts/titles/index.php?filter=Laura+benjamin
Coming for your CDMO shares :) just as Laura Benjamin is scheduled to speak at SITC 2019 Nov 6-10 ....
Laura Benjamin - CEO Oncologie Inc re: PS Targeting biomarkers Avid Bioservices CDMO
https://podcasts.apple.com/us/podcast/laura-benjamin-oncologie-part-of-the-nametag-series/id1088325796?i=1000450524353
I disagree
Min Yue leaves Eli Lilly / US based Green Valley Pharmaceuticals for China based, parent company and approved PS Targeting drug approved for Alzheimer's now
Just as Eli Lilly / Omeros published the PS Targeting relevance Sept 10, 2019 ...knowing Min Yue leaves with IP asset material info
Targeting flipped PS has always been the target...just ask Lockheed Martin with their Targeting of flipped PS patent approved in Feb 2017 when Stafford arrived on scene
Patent Inventor
Byron W. Tietjen
Paul Declan Mountcastle
Svetlana Monakhova Bachmann
https://pubchem.ncbi.nlm.nih.gov/patent/US9572918
___
Don't worry.... ALL info has been forwarded and I know some don't like so we shall see how this plays out
INmune Bio low profile .... ties Xencor and Merck
Ties Raymond J Tesi ....ties SonosBio
Edgardo ( Ed) Baracchini - CBO at Xencor
Byron W. Tietjen - patent ties Lockheed Martin
___
SITC 2019 Oncologie CEO Laura Benjamin speaking this week on PS Targeting Biomarkers etc
I have never known of a shareholder for Avid CDMO that likes to hide the facts...but China changed it's laws and can approve drugs based on surrogate endpoints / Biomarkers discovered in US now
Time for everyone to wake up and ask why Ampersand is shelling out more CDMOs like Arranta on Thermofisher deals and remains QUIET on Avid CDMO
PS Targeting patents REQUIRED for Lockheed Martin
Isolating flipped PS and EXTRACTION from blood requires Avid Bioservices CDMO to be handed ASTRONOMICAL royalties and milestones and manufacturing for any related Targeting of the IP
Some are becoming concerned and worried that NEW IIS are becoming informed and I notice Lockheed Martin stumbled into blood filtering on their ocean water filtering projects ....and the patent was awarded in Feb 2017 ...right when John Springs Stafford shows up : )
Stay tuned and send all material into DOJ FBI SEC and FDA so all are forewarned that Ampersand Capital may be playing dumb
__________
Graphene-based filter for isolating a substance from blood
2013/06/21
A device isolates a substance from blood. The substance includes particles with an effective diameter that is within a range defined by effective diameters of constituents of blood. The device comprises a first sheet of graphene including a first plurality of apertures. The first plurality of apertures are configured to pass objects with an effective diameter less than or equal to the effective diameter of the particles of the substance. The device comprises a second sheet of graphene including a second plurality of apertures. The second plurality of apertures are configured to pass objects with an effective diameter less than the effective diameter of the particles of the substance. The device may be configured to include a conduit system. The device may be configured to operate according to a reversible cycle.
http://patft.uspto.gov/netacgi/nph-Parser?d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9572918.PN.&OS=PN/9572918&RS=PN/9572918
Patent Inventor
Byron W. Tietjen
Paul Declan Mountcastle
Svetlana Monakhova Bachmann
https://pubchem.ncbi.nlm.nih.gov/patent/US9572918
PS Targeting and all IP related data including the Bavituximab treated patients are being HIDDEN from public and all because some Merckly Big Pharmas want it for themselves it seems....and will the SEC FBI DOJ FDA etc etc do their jobs without being lobbied to not disrupt the Big Pharma Cartel ??
Face the facts ...the late Dr Thorpe likely murdered in his lab to have PS Targeting IP controlled going forward and has it been controlled ?
No...just look at prior posts and FBI involvement with monitoring work and personal emails from TOP medical institutions like MD Anderson to Memorial Sloan Kettering and dozens more which includes Indiana
Maybe instead of hiding advances in medicine...all related to PS Targeting IP and risk others jumping on the same IP yet they MAY call it that they are Targeting something else!
Did Min Yue work for US based Green Valley and learn things related to PS Targeting (which is why Omeros went public with the facts that there are two brakes and PS Targeting is required ....then Min Yue on the record to being with parent company China based Green Valley and now they filed for Alzheimer's approval first.
Let's face it ... PS Targeting ALWAYS had been the story ...yet John Springs Stafford tried to tell investors otherwise
A bonus this morning for those paying attention....remember the "Lockheed Martin" patent that would REQUIRE PS Targeting patents ...well PAV#1 on Min Yue Linkedin profile is Lockheed Martin. I said the same for PAV#1 being Brigitte Phan of Allergan immediately after the death of Dr Phil Thorpe and we all know Brigitte Phan was involver with a medical device patent with Peregrine Ramone Valencia and others
Arranta CEO Mark Bamforth -
650 Pleasant St Watertown MA plans ...a little Avid expansion would fit nice or Ampersand would have some explaining to do on timeline of events and knowledge know how ....as Thermofisher will not just align themselves with Arranta without a plan of Biomarkers based on PS Targeting
So a strategic investment by Thermofisher? Rick Hancock BOD already told us that they considered expanding ....as they race to finish Arranta ...a little conflict? Hmm
Avid also told us they would consider investment by Thermofisher to supply equipment for what in return ??
Ampersand on thin ice as it looks to be clear conflicts in interest...unless they are failing to tell something ....yet
https://www.watertown-ma.gov/DocumentCenter/View/28054/05-Arranta-Site-Plan-Commitments---Sept-2019
_____
Ampersand Capital new CDMOs such as Arranta KNOW PS Targeting biomarkers led them to some gut..sy quick decisions to ramp up CDMOs because Avid Bioservices needs to expand...and quick
_____
China approves Alzheimer's drug, inviting fresh debate in field with few successes
Nov 4, 2019
...
...
Reducing neuroinflammation is one of the proposed mechanisms of action for oligomannate, which Green Valley says reconditions dysbiosis of gut microbiota as well as reduces amyloid protein deposition.
Links between bacteria in the gut and Alzheimer's have been proposed before, and researchers from Green Valley made the case for oligomannate's beneficial role via this pathway in a September 2019 paper published in Cell Research.
"There is no question that this data further supports the emerging idea that modulation of the gut microbiome via treatments such as GV-971 or other strategies should be further explored as novel strategies to slow the progression of AD," wrote researchers from Washington University School of Medicine in St. Louis, in an accompanying piece. GV-971 is another name used by Green Valley for oligomannate.
..
..
https://www.biopharmadive.com/news/china-alzheimers-drug-oligomannate-approval-green-valley/566540/
_______________
Arranta Bio announces $82M in new funding, and a strategic partnership with Thermo Fisher Scientific
November 2, 2019
...
...
Arranta Bio announced the completion of an $82 million funding round and a strategic partnership with Thermo Fisher Scientific.
Formed in May 2019, Arrantas goal is to be the best-in-class microbiome contract development and manufacturing organization (CDMO). The business provides live biotherapeutic products (LBPs) for microbiome pioneers by bacterial fermentation, isolation, drying and encapsulation.
Arrantas funding round was completed with sole institutional investor, Ampersand Capital Partners, company founders and colleagues, and a strategic investment from Thermo Fisher. Mark Bamforth, Arrantas Founder and CEO, said,
...
...
...
Over the last decade, there has been rapid acceleration in scientific understanding of the composition and functions of the gut microbiota. Arranta is proud to be building a business to support the supply needs of these innovators.
...
...
http://www.microbiometimes.com/arranta-bio-announces-82m-in-new-funding-and-a-strategic-partnership-with-thermo-fisher-scientific/
Laura Benjamin and team with PS Targeting based Biomarkers on the way ...
_____
SITC 2019
Nov 6-10, 2019
.....
.....
....
P108
Working Towards Precision Medicine of the Tumor Microenvironment
Kristen Strand-Tibbitts, PhD;
Kyung Kim, PhD;
Jeeyun Kim;
Seung-Tae Kim;
Jung-Yong Hong;
Laura Benjamin;
Kristen Strand-Tibbitts, PhD;
Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Biomarkers; Gene expression; Solid tumors; Targeted therapy; Tumor microenvironment
All odd numbered posters will be presented on Friday, November 8, 2019, while even numbered posters will be presented on Saturday, November 9, 2019.
Posters will be on display from 7 a.m. - 8 p.m., with the presenting authors required to be at their posters during lunch (12:30 - 2 p.m. on Friday, Nov. 8, and 12:35 - 2:05 p.m. on Saturday, Nov. 9) and also during the poster reception (6:30 - 8p.m. on Friday, Nov. 8, and 7 - 8:30 p.m. on Saturday, Nov. 9).
https://sitc.sitcancer.org/2019/abstracts/titles/index.php?filter=Laura+Benjamin
One never knows what else is on the way..
Nov. 5, 2019 Embargo Lifted and Full Regular and Late-Breaking Abstracts Made Public at 8 a.m. EST
Regular Abstract Supplement Published in JITC
https://www.sitcancer.org/2019/abstracts/abstract-information
Jianda Yuan (Merck) to Raphael Clymes (Xencor) to Oncologie to Thomas W Dubensky (ex Immune Design PS Targeting patents w/Merck) may be Tempest to tell how PS Targeting required especially with BGB324 BerGenBio ties to Rolf Brekken / Longen Zhou and many more ...Many well aware especially some new NEW IIS : )
Poster Symposium
Time:
Location:
Co-Chairs:
5:30 – 7:30 p.m.
Potomac Ballroom CD
Bernard A. Fox, PhD – Earle A. Chiles Research Institute, Providence Cancer Institute
Roberta Zappasodi, PhD - Memorial Sloan Kettering Institute
...
...
Session 204: Immune Checkpoints: Newer Targets and Update on Combinations
Time:
Location:
Co-Chairs: 2:00 – 4:20 p.m.
Potomac Ballroom
Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center
Ahmad A. Tarhini, MD, PhD – Moffitt Comprehensive Cancer Center and
Research Institute
....
....
5:10 p.m. (O26) A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysis
Matthew G. Krebs, MD, PhD –The University of Manchester
...
...
https://www.sitcancer.org/2019/program/annual-meeting-schedule-2019-old
I am sure Lain Baird / Julie Baird (Glasgow UK ties ... ) know and interesting how Roger Lias departed and immediately after Lain Baird publicly on record co-founded "Arranta CDMO " with Avid CDMO Mark Bamforth...
You are correct though the BOD could have clarified things but they only want certain ones to know
I am sure ThermoFisher knows as well.. as they have been to 650 Pleasant St Watertown MA for some BIG plans
https://www.loopnet.com/Listing/650-Pleasant-St-Watertown-MA/14771340/
Maybe focus on Tatiana Kevork Carlson ex Peregrine ex Halozyme now Merckly Retrophin ...and what the heck, bring in Shelley Suggett to explain some things ..
Bring in John Springs Stafford as well
Bring em all... looks like more trying to push retail out
Skin in the game is good..but Ampersand Capital hiding any skin possible over at Avid Bioservices CDMO
Avid BOD already said they are profitable...yet hide top customer and hide the very real need to expand NOW
So why would Ampersand start lining up CDMOs such as TriPharm to MedPharm to Arranta ( Watertown MA close to Oncologie Inc ) and instead of fiduciary duty to increase shareholder value EARLIER, they take the money and circumvent Avid Shareholders and pour it into other CDMOs and I imagine all should demand where such scientific knowledge was acquired ? At ThermoFisher Scientific ....where they discovered it from PS Targeting ...and let us bring Jason H Stafford and a slew of others for depositions
All best wake up and send all those complaints into FDA ( where Bavi treated patients then moving to Keytruda ) remains hidden and closed to public, into SEC where Ampersand colleagues invest illegally??...and FBI DOJ etc
PS Targeting material info is being used to further advance others own agenda before Avid Bioservices shareholders
I suspect Ampersand will try and make things somewhat right ...but where did the $82 Million come from....break it down for us Ampersand because you have BODs on Avid that are not fulfilling fiduciary duties
___
Arranta Bio Gets $82 Million in Funding, Forms Strategic Partnership with Thermo Fisher
Nov 01, 2019
By BioPharm International Editors
On Oct. 30, 2019, Arranta Bio, a Watertown, MA-based microbiome contract development and manufacturing organization, announced that it has completed an $82-million round of funding and established a strategic partnership with Thermo Fisher Scientific. Arranta provides live biopharmaceutical products (LBPs) for microbiome researchers through bacterial fermentation, isolation, drying, and encapsulation.
Arranta is establishing late clinical and commercial-ready capacity at a new facility in its Watertown headquarters, which will come online mid-2020.
Arranta's funding round was completed with Ampersand Capital Partners, company founders and colleagues, and a strategic investment from Thermo Fisher. "The microbiome is an expanding area of clinical development with the potential to impact many serious diseases, and Arranta is focused on helping pioneering companies in this field with a reliable, high-quality clinical and eventually commercial supply," said Mark Bamforth, Arranta's founder and CEO, in a company press release.
By partnering with Thermo Fisher, Arranta will have access to the company's full suite of products and services and will provide materials to Thermo Fisher for use in gene therapy production. "We are pleased to be able to partner with the Arranta team to support customers in their clinical development of novel biopharmaceuticals to improve patient health," stated Michel Lagarde, executive vice-president for Thermo Fisher, in the press release.
According to Arranta, almost 200 companies are actively exploring the linkage between the microbiome—millions of bacteria, fungi, protozoa, and viruses that live inside and on the human body—and diseases with the goal of identifying therapeutic targets. The microbiome is called the second genome by scientists, and the number of genes in the microbes making up one person's microbiome is 200 times the number in the human genome, according to the company. This past decade has particularly seen a rapid acceleration in scientific understanding of the composition and functions of the gut microbiota.
Source: Arranta Bio
http://www.biopharminternational.com/arranta-bio-gets-82-million-funding-forms-strategic-partnership-thermo-fisher
I noticed and Dr Wolchok was involved there as well...
Ampersand Capital - Patrick Walsh and Mark Bamforth making deals and after Avid Bioservices BODs seem to hide info but Bamforth seems to have no problem with nee CDMO Arranta as they don't hide their strategic dealings with Thermofisher and Ampersand is SOLE backer with employees and colleagues
....and Avid CDMO they HIDE all possible info
It is fact that Avid needs expansion and Ampersand now had 3+ tied to NEW CDMOs that they will divert new business
Funny how they bring over Lana Gladstein when it is Avid CDMO that will need the IP lawyer buy they HIDE all IP related matters re: Avid
Immune Ventures to Inmune Bio ...all tied to Xencor and Merck
I wonder how John Springs Stafford is doing these days, has he responded to any calls lately ?
Name and Address(1)
Common Stock
Owned
Number of
Shares Exercisable Within 60 Days
Percentage of Common Stock
Executive Officers and Directors
Raymond J. Tesi
1,503,333
255,554
(1)(2)
20.17 %
David J. Moss
1,186,667
255,554
(1)(3)
16.54 %
Mark Lowdel
1,503,333
183,326
(1)(4)
19.34 %
Tim Schroeder
166,667
24,000
(5)
2 %
J. Kelly Ganjei
24,000
(6)
*%
David Szymkowski
1,585,000
108,000
(7)
19.42 %
Scott Juda, JD
24,000
(10)
*%
Officers and Directors as a group (7 individuals)
5,945,000
874,434
78.21 %
Beneficial owners of more than 5%
Toucan Capital Fund III (8)
700,000
8 %
Xencor Inc. (9)
1,585,000
18.18 %
Looks like Xencor likes Inmune that both like PS Targeting ...
____________
John S Stafford and Bruce Carter voted into Xencor BOD 2015
Mirati BOD Bruce Carter ties Rolf Brekken and now wonder why Mirati racing for approval now
____________________
ISSUER: Xencor, Inc.
TICKER: XNCR CUSIP: 98401F105
MEETING DATE: 6/9/2015
FOR/AGAINST
PROPOSAL: PROPOSED BY VOTED? VOTE CAST MGMT
PROPOSAL #1.1: ELECT DIRECTOR BRUCE L.A. CARTER ISSUER YES FOR FOR
PROPOSAL #1.2: ELECT DIRECTOR ROBERT F. BALTERA, JR. ISSUER YES FOR FOR
PROPOSAL #1.3: ELECT DIRECTOR BASSIL I. DAHIYAT ISSUER YES FOR FOR
PROPOSAL #1.4: ELECT DIRECTOR JONATHAN FLEMING ISSUER YES FOR FOR
PROPOSAL #1.5: ELECT DIRECTOR KURT GUSTAFSON ISSUER YES FOR FOR
PROPOSAL #1.6: ELECT DIRECTOR A. BRUCE MONTGOMERY ISSUER YES FOR FOR
PROPOSAL #1.7: ELECT DIRECTOR JOHN S. STAFFORD, III ISSUER YES FOR FOR
PROPOSAL #2: RATIFY BDO USA, LLP AS AUDITORS ISSUER
_____
Targeting plasma membrane phosphatidylserine content to inhibit oncogenic KRAS function
Walaa E Kattan, Wei Chen, Xiaoping Ma, Tien Hung Lan, Dharini van der Hoeven, Ransome van der Hoeven, View ORCID ProfileJohn F Hancock Correspondence email
Published 26 August 2019
https://www.life-science-alliance.org/content/2/5/e201900431
____
Feb 2019
https://med.uth.edu/news/2019/02/04/patent-protects-new-role-for-old-drug-that-shows-promise-for-fighting-cancer/
The patent is on both the screening method and the new use for fendiline as an anti-cancer therapeutic. The next step is to improve the drug in ways that make it more efficacious and marketable.
Patent protects new role for old drug that shows promise for fighting cancer
Dr. Dharini van der Hoeven of the School of Dentistry and Dr. John F. Hancock of The Brown Foundation Institute of Molecular Medicine at UTHealth, share a patent on a new approach for treating cancer. Photo by Dwight C. Andrews.
UTHealth Houston has patented a new approach for treating cancer by targeting a mutation found in up to 25 percent of cancers overall and implicated in about 50 percent of cancer deaths.
The patent, "Method and Composition for Use in K-RAS Mediated Disorders," represents a discovery that could change survival rates in a wide variety of hard-to-treat cancers.
â??Ninety-five percent of pancreatic cancers are due to the K-RAS mutation,â? said UTHealth School of Dentistry Associate Professor Dharini van der Hoeven, PhD, MSc, who shares credit for the patent with her mentor, John F. Hancock,MA, MB, BChir, PhD, ScD, professor and chair, Department of Integrative Biology and Pharmacology at McGovern Medical School at UTHealth, vice dean of research, and executive director of the Brown Foundation Institute of Molecular Medicine.
The key is an old drug, fendiline, used in the past to treat angina and other cardiac conditions. In animal studies, fendiline inhibited the K-RAS protein, which in turn inhibited cancer. It has not yet been tested as a cancer treatment for humans.
Van der Hoeven was a research fellow in Hancocks lab at the medical school when she and another fellow, Kwang-Jin Cho, PhD, began screening small-molecule libraries using a novel, high-throughput screening method they developed to look for compounds that might inhibit K-RAS, a target chosen because of its prevalence in cancer.
"Using this method, we screened entire drug libraries, close to 30,000 molecules," van der Hoeven said. Fendiline was one of the molecules identified that showed great promise for inhibiting K-RAS.
It was a promise that held up in animal studies.
The patent is on both the screening method and the new use for fendiline as an anti-cancer therapeutic. The next step is to improve the drug in ways that make it more efficacious and marketable. Funding so far has come from the Cancer Prevention and Research Institute of Texas, with Hancock as principal investigator and van der Hoeven as co-investigator.
Van der Hoeven is also investigating use of fendiline on oral cancers, which express H-RAS, a different isoform of mutated RAS. Early results have been exciting, she said.
"To contribute to something like this, for me, is more than getting the patent and the potential collaborating with pharmaceutical companies," she said. "Its about discovering something that could potentially help people who suffer so much from cancer. Thats what gives me fulfillment."
October 29, 2019
Flipping the dogma – phosphatidylserine in non-apoptotic cell death
Inbar Shlomovitz,
Mary Speir &
Motti Gerlic
Cell Communication and Signaling volume 17, Article number: 139 (2019) | Cite this article
Abstract
The exposure of phosphatidylserine (PS) on the outer plasma membrane has long been considered a unique feature of apoptotic cells. Together with other “eat me” signals, it enables the recognition and phagocytosis of dying cells (efferocytosis), helping to explain the immunologically-silent nature of apoptosis. Recently, however, PS exposure has also been reported in non-apoptotic forms of regulated inflammatory cell death, such as necroptosis, challenging previous dogma. In this review, we outline the evidence for PS exposure in non-apoptotic cells and extracellular vesicles (EVs), and discuss possible mechanisms based on our knowledge of apoptotic-PS exposure. In addition, we examine the outcomes of non-apoptotic PS exposure, including the reversibility of cell death, efferocytosis, and consequent inflammation. By examining PS biology, we challenge the established approach of distinguishing apoptosis from other cell death pathways by AnnexinV staining of PS externalization. Finally, we re-evaluate how PS exposure is thought to define apoptosis as an immunologically silent process distinct from other non-apoptotic and inflammatory cell death pathways. Ultimately, we suggest that a complete understanding of how regulated cell death processes affect the immune system is far from being fully elucidated.
...
...
https://biosignaling.biomedcentral.com/articles/10.1186/s12964-019-0437-0
CP was correct the Microsoft of Biotechnology and even Lockheed Martin REQUIRES PS Targeting and Xencor David Szymkowski KNOWS 100%
_________
Patents by Inventor Svetlana Monakhova BACHMANN
Svetlana Monakhova BACHMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
GRAPHENE-BASED FILTER FOR ISOLATING A SUBSTANCE FROM BLOOD
Publication number: 20170128891
Abstract: A device isolates a substance from blood. The substance includes particles with an effective diameter that is within a range defined by effective diameters of constituents of blood. The device comprises a first sheet of graphene including a first plurality of apertures. The first plurality of apertures are configured to pass objects with an effective diameter less than or equal to the effective diameter of the particles of the substance. The device comprises a second sheet of graphene including a second plurality of apertures. The second plurality of apertures are configured to pass objects with an effective diameter less than the effective diameter of the particles of the substance. The device may be configured to include a conduit system. The device may be configured to operate according to a reversible cycle.
Type: Application
Filed: January 19, 2017
Publication date: May 11, 2017
Applicant: Lockheed Martin Corporation
Inventors:
Svetlana Monakhova Bachmann, Paul Declan Mountcastle,
Byron W. Tietjen
https://patents.justia.com/inventor/svetlana-monakhova-bachmann
_________
Byron W Tietjen ties to SonosBio and Keystone etc etc ... brings us CLOSER to Xencor and John Springs Stafford LIED it seems to Avid Bioservices CDMO shareholders so who sent him over to divert the IP to Oncologie Inc ?
... some are trying stealthy maneuvers to hide PS Targeting that is required for many Graphene Based Material things ...
________
Contact Information
Sonosbio Inc
7503 Jones Ave NW
Seattle, WA 98117
Contact: Raymond Tesi
Title: Chief Executive Officer
Phone: (510) 396-5709
Website:
Sonosbio Inc is the only company located at 7503 Jones Ave NW, Seattle, WA 98117
_______
https://inmunebio.com/index.php/en/about/directors
Raymond J. Tesi, MD
Chairman
Dr. Tesi has been Chairman since the formation of the Company in September 2015. Since December 2016, Dr. Tesi has been a Director of Savant HWP, an addiction medicine company. From November 2011 to May 2015, Dr. Tesi was CEO, President and Acting Chief Medical Officer of FPRT Bio Inc., a development-stage biotech company formed to develop XPro1595 for the treatment of neurodegenerative disease and other inflammatory diseases. From November 2010 to October 2011, Dr. Tesi was Chief Medical Officer of Adienne SRL, an emerging biotech company in Bergamo, Italy focused on products to treat patients with hematologic malignancy. From June 2007 to September 2010, Dr. Tesi was CEO and President of Coronado Biosciences, a company he founded. Dr. Tesi received his MD degree from Washington University School of Medicine in 1982. Dr. Tesi has been a licensed physician since 1982 and Fellow of the American College of Surgery since 1991.
Dr. Tesi's significant experience with our licensed technology and his experience as a transplant surgeon, entrepreneur, investor and director of start-up biopharmaceutical companies were instrumental in his selection as a member of the Board of Directors.
David Szymkowski, PhD
David E. Szymkowski leads the immunology group as Vice President of Cell Biology at Xencor Inc where he is focused on translational development of Fc-engineered and bispecific antibodies for the treatment of autoimmune diseases, allergic diseases, and cancer. Prior to joining Xencor in 2002, Dr. Szymkowski was a principal scientist in the respiratory group at Roche Bioscience in Palo Alto, CA. Previously, he was a virology program leader at Roche Pharmaceuticals in the U.K. With 25 years of big pharma and biotech R&D experience at Roche and at Xencor, Dr. Szymkowski has been instrumental in 10 IND submissions, coauthored over forty papers and reviews, is an inventor on over a dozen patents, and speaks frequently on the development of antibody therapeutics and other biologics. Dr. Szymkowski has contributed to the advancement of numerous antibody drugs into clinical trials for lupus, asthma, allergy, and hematological and solid tumors. He received his B.A. at Johns Hopkins University and his Ph.D. in molecular and cell biology from Penn State, and completed a postdoc at the Imperial Cancer Research Fund (U.K.).
_______
The list is long and puzzle pieces ALL going to shine
Avid Bioservices CDMO shareholders best SEND in complaints to SEC DOJ FBI FDA and news organizations ...some are trying very hard to keep things quiet
Yes, Ampersand Capital would like another CDMO on top of Avid CDMO, MedPharm CDMO, TriPharm CDMO ...New England Peptides etc ...it is amazing the Richard Charpie ties to Merck and how some at Ampersand KNOW the PS Targeting Biomarkers are worth Billions ...and Merckly breadcrumb deals accepted
The late Robert A Charpie would not likely accept such deals to hide PS Targeting in exchange for manufacturing contracts ...and maybe some Nantucketers will agree
Nondisclosure agreements voided in lawsuits and I imagine the Merck ties will place John Springs Stafford and Ampersand in a bad spotlight
Ampersand Capital knows about stock transfer possibly but shouldn't ALL Avid Bioservices shareholders be urgently concerned that TriPharm CDMO is ramping up for subcutaneous clients ...and TriPharm has Mark Bamforth and Patrick D Walsh diverting new and overflow subcutaneous client work from Avid CDMO to TriPharm
So TriPharm getting fully funded as Rick Hancock says no plans for Ampersand to fund bigger expansions ....when TriPharm looks to be diverting profits to TriPharm
Ampersand Capital playing dumb as Mercks lacky ....hell, Mark Bamforth bio from TriPharm page DOES NOT even mention Avid Bioservices so why diversion of client contracts??
Avid CDMO best continue sending in those certified letters / complaints etc to SEC FBI DOJ FDA etc because shade $hit going on as PPS suppressed as PS flipping inside Ampersand Capital cells and can not be trusted it seems.
_____
TriPharm Services announces creation of pharmaceutical manufacturing center
Capabilities Address Shortage of Qualified Parenteral Manufacturing Options in the U.S.
MORRISVILLE, NC, October 16, 2019
TriPharm Services, a new contract development and manufacturing organization (CDMO), is commissioning a new specialized manufacturing operation utilizing the latest isolator manufacturing equipment. The center of excellence specializes in injectable pharmaceutical capabilities including flexible manufacturing solutions for liquid and lyophilized products.
The facility, located at 627 Davis Drive in Morrisville and totaling 32,000 square feet, will offer four isolator filling suites and the highest level of control available for Grade A processing of client biologic and small molecule products. Featuring state-of-the-art equipment, the facility has eight multi-purpose cleanrooms to support manufacturing operations, along with modern, specialized utility systems to scale to client requirements.
Cofounders Patrick Walsh and Eric Evans have a long track record of creating high-growth organizations in the pharma industry and are backed by healthcare private equity firm Ampersand Capital Partners.
"TriPharm brings a new option to clients seeking modern, well-equipped manufacturing with an experienced leadership team," said Walsh.
"We are committed to providing a unique, high-quality service to our clients, given the global need for reliable, flexible and scalable manufacturing of injectable pharmaceuticals."
The state-of-the-art equipment and facility are set to be fully operable in the second quarter of 2020.
ABOUT TRIPHARM:
TriPharm is a CDMO offering parenteral manufacturing options for pharma and biotechnology clients. The formula is simple: Common sense, a founders mentality, and high-quality standards are applied vigorously around a relentless focus on client deliverables. www.TriPharm.com
ABOUT AMPERSAND CAPITAL PARTNERS:
Founded in 1988, Ampersand Capital Partners is a middle-market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of our core healthcare sectors, including Avista Pharma, Brammer Bio, Confluent Medical, Genoptix, Talecris Biotherapeutics, and Viracor-IBT Laboratories.
https://www.tripharm.com/tripharm-services-announces-creation-of-pharmaceutical-manufacturing-center/
_________
Mark R. Bamforth
Mark Bamforth founded a new CDMO, Arranta Bio, in May 2019.
Previously, Mark founded Brammer Bio in 2015, a best-in-class viral vector contract development and manufacturing organization (CDMO) supporting cell and gene therapies. Brammers team grew from 110 in 2016 with the addition of 100 from the acquisition of two Biogen commercial facilities, to over 600 at the time of its acquisition by Thermo Fisher Scientific in April 2019.
In 2010, Mark founded a biologics CDMO, Gallus BioPharmaceuticals, and acquired a world-class facility and team of 160 from J&J with a commercial supply agreement. Gallus tripled through organic growth and merging with Laureate Biopharma. Gallus was sold to DPx Holdings B.V. in Sept. 2014.
Mark previously spent 22 years in the UK and USA running a global manufacturing operation and a pharmaceutical CMO business for Genzyme and served as a corporate officer for 9 years.
He began his career as a petroleum engineer exploring for North Sea oil with Britoil, then as a chemical engineer in the whiskey industry with Whitbread.
Mark serves on the boards of Avid Bioservices, MassBio, Wentworth Institute of Technology, and Entrepreneurial Scotland. He has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College.
https://www.tripharm.com/about-us/mark-r-bamforth/
_______
Patrick D. Walsh
Pat has over thirty-five years of experience in the healthcare industry with extensive experience directing pharmaceutical manufacturing operations on a global scale in parenteral, API, specialty pharmaceutical, formulation, manufacturing and analytical contract development organizations.
Most recently, he served as the CEO of Avista Pharma Solutions and drove the rapid growth of the business, resulting in a pre-emptive sale of the company to Cambrex Corp in January 2019 for $252 million. Before Avista, he was CEO of AAIPharma Services and led the successful growth strategy, culminating in the sale of the company for 4.6 times return on invested capital.
Pat serves as an independent director of Avid Bioservices, MedPharm, and ANI Pharma. Prior board of director roles includes serving as Chairman of Brammer Bio and numerous other pharma and biotechnology companies.
https://www.tripharm.com/about-us/patrick-d-walsh-2/
_______
Trevor L. Wahlbrink
Mr. Wahlbrink is a Partner at private equity firm Ampersand Capital, and a member of the Ampersand team since 2012. Prior to his time at Ampersand, he was an Associate at Morgan Keegan where he worked on a number of leveraged acquisitions and recapitalizations of middle market companies. Prior to Morgan Keegan, Trevor was at Covington Associates, a specialty investment bank, where he focused on healthcare M&A transactions. Trevors in board seats have included Avista Pharma Solutions, Confluent, Elite One and ETE Medical. Trevor holds a M.S. and B.S. in Accounting and Finance from Boston College and is a CFA charter holder.
https://www.tripharm.com/about-us/trevor-l-wahlbrink/
______
Herbert H. Hooper
Mr. Hooper is the Managing Partner at Ampersand Capital, where he has worked since 2002. He brings an extensive background working with healthcare entrepreneurs and high growth organizations and has served on the board of numerous healthcare companies. His current and past board seats include ACLARA, Brammer Bio, Avista Pharma Services, GENEWIZ, Genoptix and Viracor-IBT Laboratories. He also serves on the College of Chemistry Advisory Board for the University of California, Berkeley. Herb holds a B.S. in Chemical Engineering from North Carolina State and a Ph.D. in Chemical Engineering from the University of California, Berkeley.
https://www.tripharm.com/about-us/herbert-h-hooper/
________
Anita Kavlie .. and others, including Wayne Gombotz KNOW PS Targeting required as patents filed with key players and some sing from Omeros that just published PS Targeting is required
Jay Venkatesan over at Alpine Immune Sciences...remember him from Ayer Capital Management ? : ) ...with Al Gore sidekick and they were forced to close due to illegal trading of Peregrine Pharmaceuticals and now in the midst of PS Targeting .....like Hotel California no one leaves
MORE to come...I can promise that and ex Omeros Clark E Tedford can't even deny the protein pathways that PROVE PS Targeting required
________
Compositions for Inhibiting MASP-2 Dependent Complement Activation
Publication number: 20190119402
Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
Type: Application
Filed: July 13, 2018
Publication date: April 25, 2019
Inventors:
Thomas Dudler,
Wayne R. Gombotz,
James Brian Parent,
Clark E. Tedford,
Anita Kavlie,
Urs Beat Hagemann,
Herald Reiersen,
Sergej Kiprijanov
https://patents.justia.com/inventor/anita-kavlie
________
Wayne Gombotz
Chief Technology Officer at Alpine Immune Sciences
Alpine Immune Sciences
University of Washington
Seattle, Washington
Experience
Alpine Immune Sciences
Chief Technology Officer
Alpine Immune Sciences
Jun 2019 – Present5 months
Greater Seattle Area
Alpine Immune Sciences
Chief Technology Officer
Alpine Immune Sciences
Jun 2019 – Present5 months
Greater Seattle Area
Immune Design
Chief Development Officer
Immune Design
Oct 2011 – Present8 years 1 month
Seattle, WA
Omeros Corporation
Vice President Pharmaceutical Operations
Omeros Corporation
2005 – 2011
6 years
Seattle, WA
Corixa Corp.
Vice President Process Science & Pharmaceutical Development
Corixa Corp.
Sep 2002 – Mar 2005
2 years 7 months
Immunex Corp
Sr. Director Analytical Chemistry & Formulation
Immunex Corp
1993 – 20029 years
Bristol-Myers Squibb
Sr. Research Investigator
Bristol-Myers Squibb
1990 – 19933 years
Greater Seattle Area
Enzytech, Inc.
Research Scientist
Enzytech, Inc.
1988 – 19902 years
Cambridge, MA
JNCJ, many believe in PS Targeting and as the facts come in, it will be sound science and a disturbance to Big Pharma? Hell yes
I will pick out just one of the MANY that can't deny it anymore and you also think Univ of Texas Board of Regents is aware? YES
John F Hancock knows well how astronomical PS Targeting is right now
____________
PS Targeting patent filed when they did not realize lol that it was PS Targeting / ...but look, 3 years later they publish research saying clearly it is PS Targeting ... so we see the bias from Board of Regents Univ of Texas System and clear conflicts of interest from Board of Regents - Univ of Texas System
_______________
Methods and compositions for use with K-ras mediated disorders
Patent number: 9474730
Abstract: Methods and compositions that can be used to identify and characterize inhibitors of K-ras localization to the plasma membrane and in doing so inhibit the signal transduction of K-ras. Such compositions can be used to treat K-ras mediated disorders, such as cancer.
Type: Grant
Filed: April 30, 2013
Date of Patent: October 25, 2016
Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Inventors: John F. Hancock, Dharini Van Der Hoeven, Kwang-Jin Cho
https://patents.justia.com/inventor/dharini-van-der-hoeven
_______________
Targeting plasma membrane phosphatidylserine content to inhibit oncogenic KRAS function
Article (PDF Available) ·
October 2019 with 51 Reads
Walaa Kattan at University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences
Walaa Kattan
University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences
Wei Chen
Xiaoping Ma
Tien Hung Lan
Dharini van der Hoeven
Ransome van der Hoeven
John F Hancock
Abstract
The small GTPase KRAS, which is frequently mutated in human cancers, must be localized to the plasma membrane (PM) for biological activity. We recently showed that the KRAS C-terminal membrane anchor exhibits exquisite lipid-binding specificity for select species of phosphatidylserine (PtdSer). We, therefore, investigated whether reducing PM PtdSer content is sufficient to abrogate KRAS oncogenesis. Oxysterol-related binding proteins ORP5 and ORP8 exchange PtdSer synthesized in the ER for phosphatidyl-4-phosphate synthesized in the PM. We show that depletion of ORP5 or ORP8 reduced PM PtdSer levels, resulting in extensive mislocalization of KRAS from the PM. Concordantly, ORP5 or ORP8 depletion significantly reduced proliferation and anchorage-independent growth of multiple KRAS-dependent cancer cell lines, and attenuated KRAS signaling in vivo. Similarly, functionally inhibiting ORP5 and ORP8 by inhibiting PI4KIIIα-mediated synthesis of phosphatidyl-4-phosphate at the PM selectively inhibited the growth of KRAS-dependent cancer cell lines over normal cells. Inhibiting KRAS function through regulating PM lipid PtdSer content may represent a viable strategy for KRAS-driven cancers.
https://www.researchgate.net/publication/335416493_Targeting_plasma_membrane_phosphatidylserine_content_to_inhibit_oncogenic_KRAS_function/fulltext/5d648dc392851c619d781a44/335416493_Targeting_plasma_membrane_phosphatidylserine_content_to_inhibit_oncogenic_KRAS_function.pdf?origin=publication_detail
No bother bringing up Fargo details yet.. I am more intrigued by David A Schaer info poached over to Pfizer and Parchoice Therapeutics latest parent surrounding PS Targeting re: CAR EXOSOMES and Michael Kalos exiting of Eli Lilly ..and so many more interesting things than Fargo and sealed court records proving PS Targeting is astronomical
____
Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types
Clinical Cancer Research
March 1, 2013
Paolo A. Ascierto,
Michael Kalos,
David A. Schaer,
Margaret K. Callahan, and
Jedd D. Wolchok
________
METHOD FOR PREPARING IMMUNE CELL EXOSOME CARRYING CHIMERIC ANTIGEN RECEPTOR AND APPLICATION THEREOF
PHARCHOICE THERAPEUTICS INC
Abstract:
(EN) Provided are a method for preparing an immune cell exosome carrying CAR obtained by isolation and an application thereof. After activating a CAR immune cell by a specific antigen, the produced exosome is subjected to further analysis, isolation, purification, and enrichment to finally obtain the immune cell exosome carrying CAR. The exosome can be used to treat a disease such as cancer and a severe infectious disease.
(FR) L'invention concerne un procédé de préparation d'un exosome de cellule immunitaire contenant un CAR obtenu par isolement, ainsi qu'une application associée. Après activation d'une cellule immunitaire CAR par un antigène spécifique, l'exosome produit est soumis à une analyse, à un isolement, à une purification et à un enrichissement supplémentaires en vue d'obtenir finalement l'exosome de cellule immunitaire contenant le CAR. L'exosome peut être utilisé pour traiter une maladie telle qu'un cancer et une maladie infectieuse grave.
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019128952
_____
I foresee PS Targeting and CDMO contracts increasing ...due to 3rd parties revealing that the IP was well worth the wait
As for Alzheimer's and all disease known to require an agent compound that easily slips pass the blood brain barrier ...there seems to be an extreme need for "surrogate endpoints" leading to MOS and those are being restricted by some that also have an extreme need for CDMO shares
I have to get all my Alzheimer's info together again ....as Biogen and PS Targeting may be making others wonder how this is aligned with Omeros that just validated that they are bringing up to date ..data ....to some conference
I guarantee that some will not want to be concerned about year end losses because Intercept has proven that once one is out...one is out of luck
What the hell is going on.... they couldn't wait till after hours for that "buy" block trade : )
Maybe we are inching closer, yet again....and now for the first time we have Betabodies ahead and PS Targeting in multiple pipelines...even Alzheimer's
Some must realize that it will be hedge fund vs hedge fund and BP vs BP ...as the FDA cant refuse to allow a third party to verify a drugs MOA AND UPDATE a drugs MOA
Stay tuned
Oncologie Inc David Malek sits with Roche at their new Roche Innovation Center
https://www.bloomberg.com/profile/person/17386326
David Malek
Rm 2503 Twr 2 1196 Century Ave Pudong New Area Shanghai, 200122 China
PHONE
86-21-3106-3487
WEBSITE
www.pivotalbiovp.cn
What is Ampersand Capital doing with all the requests that are incoming?
What are they under agreement with ...or will they realize that that ARE involved and 2 of their employees sitting on Avid BOD may not be looking into matters that ...will escalate
Even worse, they did their due diligence and buy out Interpace Diagnostics with DIRECT ties now to Merck Keytruda + Bavituxab data ....more to surface
new info to surface and with Vertex "new" PS Targeting compound and in combination with LOTS of prior info...I think Ampersand would be foolish if they are not out to maximize shareholder value and risk other info to come out showing they were part of the problem, not the solution
All should continue sending in the complaints to SEC FBI DOJ FDA and again, I ask nicely....for ALL to ask for the 100% file for the "Fairness Opinion .." given that Ampersand Capital should admit viewing while now they have to consider other options -- some things just may surprise everyone! and with CDMO receiving royalties on all IP asset based net sales..etc we are in for an eye opener
_________
Lavage lipidomics signatures in children with cystic fibrosis and protracted bacterial bronchitis.
Seidl E, et al. J Cyst Fibros. 2019.
Authors
Seidl E1, Kiermeier H1, Liebisch G2, Ballmann M3, Hesse S1, Paul-Buck K4, Ratjen F5, Rietschel E6, Griese M7.
Author information
1
Hauner Children's Hospital, Ludwig Maximilians University, German Center for Lung Research (DZL), Lindwurmstr. 4a, D-80337 Munich, Germany.
2
Institute of Clinical Chemistry and Laboratory Medicine, Regensburg University Hospital, Germany.
3
Department of Pediatric Pulmonology, University Rostock, Germany.
4
Praxis Prof. Karl Paul, Schöneberger Ufer 69, 10785 Berlin, Germany.
5
Hospital for Sick Children, University of Toronto, Canada.
6
CF-Centre, Faculty of Medicine, University of Cologne, Germany.
7
Hauner Children's Hospital, Ludwig Maximilians University, German Center for Lung Research (DZL), Lindwurmstr. 4a, D-80337 Munich, Germany. Electronic address: Matthias.griese@med.uni-muenchen.de.
Among the phospholipids, patients with CF had higher proportion of the non-surfactant membrane-lipids in the classes phosphatidylethanolamine based plasmalogens (PE P), phosphatidylethanolmine (PE) and phosphatidylserine (PS), but a lower proportion of phosphatidylcholine (PC) compared to healthy controls.
...
...
https://www.ncbi.nlm.nih.gov/m/pubmed/31029606/
Trademark "BETABODY" just updated last week
________
DATA PRESENTED AT AACR ANNUAL MEETING SUPPORT TARGETED IMMUNE REACTIVATION MECHANISM AND POTENTIAL OF PEREGRINE'S BAVITUXIMAB IN SOLID TUMOR THERAPY
April 10, 2013
...
Researchers also presented details of new PS-binding constructs(4). Termed "betabodies," the molecules consist of the PS-binding domain of the serum protein ß2-glycoprotein I (ß2GPI), fused to the constant region of an antibody. Betabodies bind to PS directly, are smaller in size and have a longer serum half-life than natural antibodies. Early studies indicate that betabodies hold potential as next-generation PS-binding agents that have the potential to be used for a broad number of applications including antibody-drug conjugates and next generation therapeutics for oncology and infectious diseases.
...
http://ir.avidbio.com/news-releases/news-release-details/data-presented-aacr-annual-meeting-support-targeted-immune
_________
Feb 12, 2018
TUSTIN, Calif. and BOSTON, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Oncologie, Inc. today announced that the companies have entered into an Asset Assignment and Purchase Agreement for Avid’s phosphatidylserine (PS)-targeting program including bavituximab. Bavituximab is an investigational immune-modulatory monoclonal antibody that targets PS, a phospholipid that inhibits the ability of immune cells to recognize and fight tumors. In addition to bavituximab, the deal includes Avid’s other PS-targeting antibodies, including betabodies, as well as certain other assets and licenses useful and/or necessary for the potential commercialization of bavituximab.
Under terms of the agreement, Avid will receive an aggregate of $8 million in upfront payments from Oncologie paid over a period of six months from the execution date of the agreement and will be eligible to receive up to $95 million in development, regulatory and commercialization milestones. Oncologie will be responsible for all future research, development and commercialization of bavituximab, and related intellectual property costs, with Avid receiving royalties on net sales that are upward tiering into the mid-teens. As part of the deal, Oncologie will also enter into an agreement with Avid for future contract development and manufacturing activities in support of bavituximab. Roth Capital Partners acted as financial advisor to Avid in this transaction, rendering a Fairness Opinion to its board of directors.
...
https://www.pm360online.com/avid-bioservices-and-oncologie-enter-into-asset-assignment-and-purchase-agreement-for-avids-ps-targeting-program-including-bavituximab/amp/
____________
Trademark for "BETABODY" updated just this month ...Oct 14, 2019
Oct 14 2019
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
https://trademarks.justia.com/862/48/betabody-86248425.html
Yes though we will see increase in IIS
I wonder how Steve Demattos (which hides his Peregrine employment on LinkedIn) and Ronald Demattos are doing ..
_____
Good luck Eli Lilly and what is Steve Demattos brothers name again...oh yes, Ronald DeMattos! : )
Say hello to Cheryl Leyns at Merck ( Dr David Holtzman her advisor etc) as she knows Alzheimer's requires PS Targeting. Imagine that...some hedge funds spend hours trying to figure some of this out.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149648134